Pedro Fraiman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Pedro Fraiman has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Clecio Godeiro-Junior
Division of Neurology, Hospital Universitário Onofre Lopes Universidade Federal do Rio Grande do Norte Natal Brazil
10 shared publications - José Luiz Pedroso
Division of General Neurology and Ataxia Unit, Department of Neurology Universidade Federal de São Paulo São Paulo Brazil
8 shared publications - Orlando Graziani Povoas Barsottini
Division of General Neurology and Ataxia Unit, Department of Neurology and Neurosurgery, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
8 shared publications José Luiz Pedroso
Division of General Neurology and Ataxia Unit, Department of Neurology and Neurosurgery Universidade Federal de São Paulo São Paulo Brazil
6 shared publications- Vinícius Lopes Braga
Undergraduate Medical Student, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (Unifesp), São Paulo (SP), Brazil
6 shared publications - Filipe Pereira Sarmento
Department of Neurological Sciences, Rush University, Chicago, IL
4 shared publications
Latest Publications
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10) , e214902
Reader Response: Clinical Reasoning: A 38-Year-Old Man With Involuntary Jerk-Like Movements and Ataxia
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10) , e214902
Reader Response: Clinical Reasoning: A 38-Year-Old Man With Involuntary Jerk-Like Movements and Ataxia
- 4 November 2026
- Published by Wiley in Movement Disorders Clinical Practice
Oculomotor Phenomenology in Cerebellar Ataxias: A Video‐Illustrated Practical Diagnostic Approach
Background: Cerebellar ataxias are a heterogeneous group of neurological disorders with overlapping clinical, genetic, and epidemiological features, arising from the dysfunction of cerebellar and extracerebellar structures, including brainstem pathways. Etiologies include autosomal dominant, autosomal recessive, mitochondrial, X‐linked, congenital, and acquired causes. Oculomotor abnormalities are common and vary across ataxia subtypes, making their recognition relevant to diagnosis. Objective: The aim of the study was to review key oculomotor abnormalities in cerebellar ataxias, illustrate their neuroanatomical basis through video‐based teaching material, and propose a structured clinical workflow for diagnostic decision‐making. Methods: A narrative literature search was conducted in PubMed (2015–2025), complemented by earlier landmark references, focusing on oculomotor phenomenology in genetic and acquired ataxias. Disorders were organized based on predominant ocular motor patterns. Six major eye movement systems—vestibulo‐ocular reflex (VOR), smooth pursuit, optokinetic reflex, saccades, gaze holding, and vergence—were reviewed, followed by characteristic abnormalities, representative video findings, and a stepwise bedside workflow. Results: Oculomotor patterns, including saccadic intrusions, gaze‐evoked and vertical nystagmus, supranuclear gaze palsies, saccadic dysmetria, slow saccades, ocular motor apraxia, impaired optokinetic responses, and VOR deficits, reflect the dysfunction of specific cerebellar and brainstem pathways. Some patterns suggest particular etiologies, including spinocerebellar ataxia type 2 (SCA2) (slow saccades), Niemann–Pick type C (vertical supranuclear gaze palsy), SCA3 (pseudoproptosis), and cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) or Friedreich ataxia (VOR deficits). Conclusions: Oculomotor abnormalities provide valuable diagnostic clues in cerebellar ataxias. Structured assessment of spontaneous eye movements, saccades, smooth pursuit, and VOR function may improve bedside phenotyping and diagnostic accuracy.
- 4 November 2026
- Published by Wiley in Movement Disorders Clinical Practice
Oculomotor Phenomenology in Cerebellar Ataxias: A Video‐Illustrated Practical Diagnostic Approach
Background: Cerebellar ataxias are a heterogeneous group of neurological disorders with overlapping clinical, genetic, and epidemiological features, arising from the dysfunction of cerebellar and extracerebellar structures, including brainstem pathways. Etiologies include autosomal dominant, autosomal recessive, mitochondrial, X‐linked, congenital, and acquired causes. Oculomotor abnormalities are common and vary across ataxia subtypes, making their recognition relevant to diagnosis. Objective: The aim of the study was to review key oculomotor abnormalities in cerebellar ataxias, illustrate their neuroanatomical basis through video‐based teaching material, and propose a structured clinical workflow for diagnostic decision‐making. Methods: A narrative literature search was conducted in PubMed (2015–2025), complemented by earlier landmark references, focusing on oculomotor phenomenology in genetic and acquired ataxias. Disorders were organized based on predominant ocular motor patterns. Six major eye movement systems—vestibulo‐ocular reflex (VOR), smooth pursuit, optokinetic reflex, saccades, gaze holding, and vergence—were reviewed, followed by characteristic abnormalities, representative video findings, and a stepwise bedside workflow. Results: Oculomotor patterns, including saccadic intrusions, gaze‐evoked and vertical nystagmus, supranuclear gaze palsies, saccadic dysmetria, slow saccades, ocular motor apraxia, impaired optokinetic responses, and VOR deficits, reflect the dysfunction of specific cerebellar and brainstem pathways. Some patterns suggest particular etiologies, including spinocerebellar ataxia type 2 (SCA2) (slow saccades), Niemann–Pick type C (vertical supranuclear gaze palsy), SCA3 (pseudoproptosis), and cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) or Friedreich ataxia (VOR deficits). Conclusions: Oculomotor abnormalities provide valuable diagnostic clues in cerebellar ataxias. Structured assessment of spontaneous eye movements, saccades, smooth pursuit, and VOR function may improve bedside phenotyping and diagnostic accuracy.
- 23 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (11) , 3031-3037
Unraveling SPG46 : Clinical, Genetic, and Neuroimaging Features
Background: SPG46 is an autosomal recessive hereditary spastic paraplegia (HSP) caused by biallelic GBA2 mutations. As a rare and still poorly understood condition, information about its clinical and genetic spectrum is scarce. Objective: This study aimed to delineate the clinical, neuroimaging, and genetic characteristics of a Brazilian SPG46 cohort. Methods: We conducted a retrospective cross‐sectional study at two referral centers, identifying nine patients from six unrelated families harboring pathogenic GBA2 variants through whole‐exome sequencing. Demographic, clinical, neuroimaging, and genetic data were systematically analyzed. Results: The cohort (4 males, 5 females) presented disease onset between 6 and 24 years (mean, 10.7). All exhibited progressive spastic paraplegia associated with cerebellar ataxia, dysarthria, and cognitive impairment. Psychiatric manifestations, sleep disturbances, skeletal deformities, and dystonia were frequent. Cerebellar atrophy was observed in four cases, whereas corpus callosum thinning, cataracts, and hearing impairment were absent. Conclusion: The recurrent GBA2 c.1365G>C;p.(Trp455Cys) variant suggests a potential founder effect and expands the phenotypic spectrum of SPG46 in Brazil.
- 23 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (11) , 3031-3037
Unraveling SPG46 : Clinical, Genetic, and Neuroimaging Features
Background: SPG46 is an autosomal recessive hereditary spastic paraplegia (HSP) caused by biallelic GBA2 mutations. As a rare and still poorly understood condition, information about its clinical and genetic spectrum is scarce. Objective: This study aimed to delineate the clinical, neuroimaging, and genetic characteristics of a Brazilian SPG46 cohort. Methods: We conducted a retrospective cross‐sectional study at two referral centers, identifying nine patients from six unrelated families harboring pathogenic GBA2 variants through whole‐exome sequencing. Demographic, clinical, neuroimaging, and genetic data were systematically analyzed. Results: The cohort (4 males, 5 females) presented disease onset between 6 and 24 years (mean, 10.7). All exhibited progressive spastic paraplegia associated with cerebellar ataxia, dysarthria, and cognitive impairment. Psychiatric manifestations, sleep disturbances, skeletal deformities, and dystonia were frequent. Cerebellar atrophy was observed in four cases, whereas corpus callosum thinning, cataracts, and hearing impairment were absent. Conclusion: The recurrent GBA2 c.1365G>C;p.(Trp455Cys) variant suggests a potential founder effect and expands the phenotypic spectrum of SPG46 in Brazil.
- 24 April 2026
- Published by BMJ in Practical Neurology
Late-onset subacute chorea
A 71-year-old woman presented with late-onset behavioural change initially diagnosed as bipolar disorder, followed 4 years later by generalised chorea and weight loss. Examination showed hyperkinetic movements with frontal and oculomotor features. An MR scan of the brain showed bilateral striatal T2 FLAIR hyperintensities. Serum and cerebrospinal fluid were positive for anticollapsin response mediator protein 5/CV2 and anti-neuronal nuclear antibody type 1/Hu antibodies, and imaging identified an underlying thoracic malignancy. She did not respond to immunotherapy and died shortly afterwards. This case highlights paraneoplastic striatal encephalitis as an important cause of late-onset chorea. Psychiatric symptoms may precede neurological features by several years, and red flags such as subacute progression, systemic symptoms and characteristic MR imaging changes should prompt early investigation for neuronal antibodies and malignancy.
- 24 April 2026
- Published by BMJ in Practical Neurology
Late-onset subacute chorea
A 71-year-old woman presented with late-onset behavioural change initially diagnosed as bipolar disorder, followed 4 years later by generalised chorea and weight loss. Examination showed hyperkinetic movements with frontal and oculomotor features. An MR scan of the brain showed bilateral striatal T2 FLAIR hyperintensities. Serum and cerebrospinal fluid were positive for anticollapsin response mediator protein 5/CV2 and anti-neuronal nuclear antibody type 1/Hu antibodies, and imaging identified an underlying thoracic malignancy. She did not respond to immunotherapy and died shortly afterwards. This case highlights paraneoplastic striatal encephalitis as an important cause of late-onset chorea. Psychiatric symptoms may precede neurological features by several years, and red flags such as subacute progression, systemic symptoms and characteristic MR imaging changes should prompt early investigation for neuronal antibodies and malignancy.
- 25 December 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 16 (5) , 1-7
Amantadine for multiple sclerosis-related fatigue: a systematic review and meta-analysis of randomized controlled trials
Fatigue affects up to 95% of individuals with multiple sclerosis (MS), significantly impairing daily functioning. Management is multidisciplinary, and although amantadine lacks U.S. FDA approval for this indication, it remains the most commonly prescribed pharmacologic option despite inconsistent supporting evidence. This systematic review and meta-analysis evaluated the effectiveness of amantadine for MS-related fatigue. We searched MEDLINE, EMBASE, and Web of Science for randomized controlled trials (RCTs) comparing amantadine to placebo in the treatment of MS-related fatigue. Statistical analyses were conducted using R. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess fatigue severity and adverse effects incidence, respectively. A random-effects model was applied to all analyses. A total of nine RCTs were included, involving 601 patients, 66% of whom received amantadine. Amantadine use was not associated with a significant reduction in fatigue severity compared to placebo (SMD -0.22; [95% CI -0.72; 0.27]; p = 0.37). However, it was associated with higher odds of insomnia (OR = 2.33; [95% CI 1.27; 4.29]; p = 0.006). This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use.
- 25 December 2025
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 16 (5) , 1-7
Amantadine for multiple sclerosis-related fatigue: a systematic review and meta-analysis of randomized controlled trials
Fatigue affects up to 95% of individuals with multiple sclerosis (MS), significantly impairing daily functioning. Management is multidisciplinary, and although amantadine lacks U.S. FDA approval for this indication, it remains the most commonly prescribed pharmacologic option despite inconsistent supporting evidence. This systematic review and meta-analysis evaluated the effectiveness of amantadine for MS-related fatigue. We searched MEDLINE, EMBASE, and Web of Science for randomized controlled trials (RCTs) comparing amantadine to placebo in the treatment of MS-related fatigue. Statistical analyses were conducted using R. Standardized mean differences (SMDs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess fatigue severity and adverse effects incidence, respectively. A random-effects model was applied to all analyses. A total of nine RCTs were included, involving 601 patients, 66% of whom received amantadine. Amantadine use was not associated with a significant reduction in fatigue severity compared to placebo (SMD -0.22; [95% CI -0.72; 0.27]; p = 0.37). However, it was associated with higher odds of insomnia (OR = 2.33; [95% CI 1.27; 4.29]; p = 0.006). This meta-analysis suggests that amantadine is not effective for treating MS-related fatigue and is associated with an increased risk of adverse effects, particularly insomnia. These results cast doubt on its continued first-line use.
- 4 December 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (4) , 389-390
From brain to spine: drop metastasis from high-grade glioma
- 4 December 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (4) , 389-390
From brain to spine: drop metastasis from high-grade glioma
- 4 December 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (4) , 376-378
Neuroichthyosis: the interplay between brain and skin
The interplay between skin and neurological disorders is well recognised, given the shared embryological origin of both skin and nervous system cells from the ectoderm. Certain cutaneous manifestations may guide the neurological workup and contribute to a more accurate diagnosis. We report a 20-year-old man with drug-resistant epilepsy and developmental regression since childhood, who had characteristic skin findings compatible with ichthyosis. Despite the broad differential diagnosis for these neurological manifestations, recognising the skin involvement was important in guiding the genetic investigation, ultimately narrowing the diagnosis to the group of neuro-ichthyotic syndromes.
- 4 December 2025
- Published by BMJ in Practical Neurology
- Vol. 26 (4) , 376-378
Neuroichthyosis: the interplay between brain and skin
The interplay between skin and neurological disorders is well recognised, given the shared embryological origin of both skin and nervous system cells from the ectoderm. Certain cutaneous manifestations may guide the neurological workup and contribute to a more accurate diagnosis. We report a 20-year-old man with drug-resistant epilepsy and developmental regression since childhood, who had characteristic skin findings compatible with ichthyosis. Despite the broad differential diagnosis for these neurological manifestations, recognising the skin involvement was important in guiding the genetic investigation, ultimately narrowing the diagnosis to the group of neuro-ichthyotic syndromes.
- 27 August 2025
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Haloperidol Versus Atypical Antipsychotics for Delirium in Hospitalized and ICU Patients: A Systematic Review and Meta-analysis
Background: While there is still debate over the benefit of antipsychotics in delirium management, surveys indicate their frequent use in clinical practice. Previous systematic reviews and meta-analyses have focused on assessing the effectiveness of antipsychotics versus placebo in delirium management. However, despite increasing access to atypical antipsychotics in hospital settings, robust analyses of studies comparing the effectiveness of haloperidol and atypical antipsychotics are lacking. Objectives: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effectiveness and safety of haloperidol versus atypical antipsychotics in the management of delirium patients. Methods: We conducted a systematic search of Medline, Scopus, and Cochrane for RCTs comparing atypical antipsychotics with haloperidol in delirium patients. Odds ratio (OR) was used to analyze dichotomous variables. Continuous outcomes were compared using mean difference (MD) and standardized mean difference (SMD). The random effects model was applied to all endpoints. Results: Eleven RCTs (n=1450 patients) met the eligibility criteria. Delirium severity (SMD, −0.03; [95% CI, −0.20 to 0.15]; P = 0.78) and overall mortality (OR, 1.26; [95% CI, 0.88-1.80]; P = 0.20) did not differ significantly between groups. However, patients treated with haloperidol had significantly higher odds of experiencing extrapyramidal symptoms compared with those treated with atypical antipsychotics (OR, 2.72; [95% CI, 1.26-5.87]; P = 0.01). Conclusions: While there were no significant differences in the effectiveness between treatments, patients treated with haloperidol had nearly a 3-fold increase in the incidence of extrapyramidal symptoms, indicating a potential advantage of atypical antipsychotics in minimizing adverse effects.
- 27 August 2025
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
Haloperidol Versus Atypical Antipsychotics for Delirium in Hospitalized and ICU Patients: A Systematic Review and Meta-analysis
Background: While there is still debate over the benefit of antipsychotics in delirium management, surveys indicate their frequent use in clinical practice. Previous systematic reviews and meta-analyses have focused on assessing the effectiveness of antipsychotics versus placebo in delirium management. However, despite increasing access to atypical antipsychotics in hospital settings, robust analyses of studies comparing the effectiveness of haloperidol and atypical antipsychotics are lacking. Objectives: To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing the effectiveness and safety of haloperidol versus atypical antipsychotics in the management of delirium patients. Methods: We conducted a systematic search of Medline, Scopus, and Cochrane for RCTs comparing atypical antipsychotics with haloperidol in delirium patients. Odds ratio (OR) was used to analyze dichotomous variables. Continuous outcomes were compared using mean difference (MD) and standardized mean difference (SMD). The random effects model was applied to all endpoints. Results: Eleven RCTs (n=1450 patients) met the eligibility criteria. Delirium severity (SMD, −0.03; [95% CI, −0.20 to 0.15]; P = 0.78) and overall mortality (OR, 1.26; [95% CI, 0.88-1.80]; P = 0.20) did not differ significantly between groups. However, patients treated with haloperidol had significantly higher odds of experiencing extrapyramidal symptoms compared with those treated with atypical antipsychotics (OR, 2.72; [95% CI, 1.26-5.87]; P = 0.01). Conclusions: While there were no significant differences in the effectiveness between treatments, patients treated with haloperidol had nearly a 3-fold increase in the incidence of extrapyramidal symptoms, indicating a potential advantage of atypical antipsychotics in minimizing adverse effects.
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213870
Teaching Video NeuroImage: Crossed Vertical Gaze Paresis
- 12 August 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (3) , e213870
Teaching Video NeuroImage: Crossed Vertical Gaze Paresis